A Double-Blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Chronic Systolic Heart Failure.

Trial Profile

A Double-Blind, Randomized, Multicenter, Parallel Group Study to Evaluate the Effects of Aliskiren, Ramipril and Combination Treatment on Plasma Concentration of Angiotensin II in Patients With Decompensated Chronic Systolic Heart Failure.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Apr 2014

At a glance

  • Drugs Aliskiren (Primary) ; Ramipril (Primary)
  • Indications Decompensated heart failure
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ESCAPE-SHF
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 23 May 2013 New source identified and integrated (European Clinical Trials Database; EudraCT2008-001035-35).
    • 02 Mar 2012 Actual patient number (123) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top